Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections
Mackow, Natalie , Shao, Wanying, Ge, Lizhao , Komarow, Lauren, Jiang, Jianping , Boutzoukas, Angelique , Chen, Liang , Herc, Erica, Doi, Yohei, Arias, Cesar A, Jacob, J, Satlin, Michael J. , Huskins, W Charles, Dhar, Sorabh, Shelburne, Samuel A, Hill, Carol, Sadler, Jacob M., Hill, Bravada M, Greenwood-Quaintance, Kerryl E, Schmidt-Malan, Suzannah M., Patel, Robin, Fowler, Vance G, Tamma, Pranita D, Kreiswirth, Barry N, Group, for the Antibacterial Resistance Leadership, Chambers, Chip, Evans, Scott, Hamasaki, Toshi, Cross, Heather, Harris, Anthony, Pettigrew, Melinda M. , Duin, David van, Boucher, Helen , Dixon, Dennis O., Ghazaryan, Varduhi , Zou, Lanling, Raterman, Erica, Samuel, Tamika, Moon, Kyung, Hanson, Kim, Holland, Thomas, Lodise, Tom, Shelburne, Sam, Banerjee, Ritu, Cosgrove, Sara, Paterson, David, Lautenbach, Ebbing , Mehigan, Maureen, Doernberg, Sarah, Doi, Yohei , Chen, Liang , Boutzoukas, Angelique E , Jiang, Jianping , Doi, Yohei , Albin, Owen , Saade, Elie , Miller, Loren G , Jacob, Jesse T , Satlin, Michael J , Krsak, Martin , Huskins, W Charles , Shelburne, Samuel A , Hill, Carol , Alby, Kevin , Sadler, Jacob M , Hill, Bravada M , Patel, Robin , Fowler, Vance G. , Tamma, Pranita D , van Duin, David , Pettigrew, M M , Evans, Scott R , Ge, Lizhao , Komarow, Lauren , Garcia‐Diaz, Julia , Herc, Erica , Arias, César A. , Albin, Owen , Saade, Elie , Jacob, Jesse T. , Kršák, Martin , Huskins, W. Charles , Dhar, Sorabh , Shelburne, Samuel A. , Hill, Carol , Alby, Kevin , Greenwood‐Quaintance, Kerryl E. , Patel, Robin , Tamma, Pranita D. , Kreiswirth, Barry N , Evans, Scott, Raterman, Erica L., Samuel, Tamika, Banerjee, Ritu , Cosgrove, Sara E. , Paterson, David L. , Mehigan, Maureen

Mayo Clinic

Clinical Infectious Diseases | March 4, 2026 | Volume: 83 | Issue: 1 | Pages: e27-e37

10.1093/cid/ciag160 | PMID 41795867 Get It

Abstract Background Ceftriaxone-resistant Escherichia coli infections are increasingly common, partially because of the emergence of E. coli sequence type 131 (ST131), including its subclade C2/H30Rx, which produce extended-spectrum β-lactamases. Methods A prospective cohort including 14 US sites, which enrolled monomicrobial ceftriaxone-resistant and susceptible E. coli bloodstream infection (BSI) cases in a 1:1 ratio, was used to compare ST131 versus non-ST131 E. coli BSI, with specific attention to E. coli ST131 C2/H30Rx. Desirability of outcome ranking was determined at 30 days after infection onset. Results This analysis included 282 patients with E. coli BSI; 43% (121/282) were E. coli ST131 and 23% (66/282) belonged to the C2/H30Rx subclade. Resistance to ceftriaxone was present in 79% (96/121) ST131, 86% (57/66) E. coli ST131 C2/H30Rx, and 27% (43/161) E. coli non-ST131. Compared to patients with non-ST131 E. coli BSI, patients with ST131 BSI were older (median 70 years, [Q1 62, Q3 76] years vs 65 years, [51, 74]; P = .005) and more often admitted from long-term care facilities (21/121 [17%] vs 7/161 [4%], P < .001). Overall and empiric carbapenem use was more frequent in the treatment of patients with ST131 BSI compared with non-ST131 BSI (overall 89/121 [74%] vs 50/161 [31%]; empiric: 58/121 [48%] vs 31/161 [19%], P < .001). Desirability of outcome ranking outcomes were similar between groups. Conclusions Most ceftriaxone-resistant E. coli from US patients with E. coli BSI belong to ST131, particularly E. coli ST131 C2/H30Rx, serving as an important driver of carbapenem use.
Recurrent pedunculated nodule on the scrotum
Amjad, Sarah , Amjad, Sarah A , Degesys, Catherine A. , Barbosa, Naiara S. , Lyon, Timothy D. , Sluzevich, Jason C.

Mayo Clinic

Clinical and Experimental Dermatology | March 4, 2026 | Volume: 51 | Issue: 8 | Pages: 1556-1558

10.1093/ced/llag106 | PMID 41783942 Get It

A 79-year-old man was referred for evaluation of a recurrent neoplasm of the left scrotum.
Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping review
Lommer, Caroline , Schroeder, Lila, Amato, Caroline, Dhakal, Kerry , Kotian, Caitlin, Quiroga, Dionisia , Paskett, E., Fu, Mei , Collins, Stephanie, King, T. A., McLaughlin, Sarah A. , Myers, Sara P. , Paskett, Electra D. , McAlearney, Ann Scheck

Mayo Clinic

Frontiers in Oncology | March 4, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.3389/fonc.2026.1751628 | PMID 41858365 Get It

Background Breast cancer-related lymphedema (BCRL) is a common and life-long adverse event affecting ~20% of breast cancer survivors. As existing non-pharmacologic management is burdensome, expensive, and variably effective, this systematic scoping review aims to identify pharmacologic and herbal agents for prevention and treatment for BCRL. Methods PubMED, Embase, Web of Science Core collection, and the Cumulative Index to Nursing and Allied Health Literature were searched for studies published in English between 1993 and 2025 that investigated the preventative or therapeutic effect of pharmacologic or herbal agents on BCRL among adult stage I-III breast cancer patients. Studies describing interventions with systemically absorbed anti-inflammatories, anti-thrombotics, anti-coagulants, and blood product components were included. Systematic reviews, protocols for ongoing clinical trials, preclinical and non-human studies, editorials, and studies not exclusive to BCRL were excluded. Three reviewers screened and extracted data between June and August 2025. The primary outcomes of interest were reduction in BCRL incidence or severity. Results Of the 217 articles screened, 37 were included in the final review. After full text review, 13 were excluded for repetitive data, non-English language, or irrelevant outcomes. The 24 studies included in the analysis investigated anti-diabetic, herbal, anti-inflammatory, anti-hypertensive, immunomodulatory, and microbiome modifying agents, and venoactive flavinoid derivates. Three studies explored the role of pharmacologic/herbal agents in BCRL prevention. While thiazolidinediones, anti-hypertensives, and non-steroidal anti-inflammatory drugs (NSAIDs) had no effect on BCRL incidence, glucagon-like peptide-1 receptor agonists (GLP-1 RA) were associated with BCRL prevention. In the 21 studies that assessed the effect of pharmacologic/herbal agents in BCRL treatment, NSAIDs/steroids, anti-hypertensives, microbiome/synbiotic supplements, and doxycycline showed no benefit and data for flavonoid-derived venoactive agents and herbal products were inconsistent. Immune-modulating therapies were associated with improved BCRL signs/symptoms in three studies. Conclusion This systematic scoping review found limited evidence suggesting that GLP-1 RAs may reduce the risk of BCRL and that immunomodulatory agents may improve signs/symptoms of BCRL. Rigorous prospective trials using standardized limb volume/edema, quality-of-life (QoL), and symptom measures and longer follow-up are needed to inform clinical practice aimed at preventing and treating BCRL. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420251055134.
Using large language models for grading CTCAE toxicity after radiation therapy for prostate cancer.
Wilson, Renthony, Osorio, Mariana Borras, Patel, Shiv, Peterson, Sarah, Zhou, Mi , Waddle, Mark R. , Mastroleo, Federico , Osorio, Mariana Borras, Shiraishi, Satomi , Foong, Anthony , Routman, David M.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 357-357

10.1200/jco.2026.44.7_suppl.357 Get It

357 Background: Prostate cancer (PCa) is the most incident cancer in adult males in the United States, and the second highest in the world. CTCAE is the standardized method to grade the severity of treatment-related adverse events (AEs), but are tedious to collect and subject to inter-observer variability. This study aimed to evaluate the performance of LLMs in automatically extracting and grading CTCAE toxicities from clinical notes and patient-reported outcomes of PCa patients from a clinical trial. Methods: A total of 55 patients from NCT02874014 trial, undergoing proton therapy (PT) for localized PCa, were included. The ground truth of CTCAE graded toxicities was obtained from the trial’s results. Clinical notes within 3 days, and the most recent patient questionnaires within 90 days of toxicity assessment were retrieved from the electronic health record. A comprehensive prompt was developed to extract and CTCAE grade toxicities from the retrieved records. LLMs used for this analysis were OpenAI GPT-4o and Gemini 2.0 Flash. Phase 1 evaluated both LLMs' performance against the ground truth. To ensure the metrics reflected the models’ performance based only on the information available in the text provided, cases where both LLMs contradicted the ground truth were manually reviewed. Phase 2 recalculated LLMs' performance metrics using this adapted ground truth. A conservative stepwise ensemble model was developed to leverage the complementary strengths of both LLMs. Results: In the conservative stepwise ensemble model, Gemini 2.0 Flash served as the initial screening platform to identify AEs in step 1. All cases with identified toxicity events were then reviewed and confirmed using OpenAI GPT-4o in step 2. This effectively reduced false positive rates while preserving high sensitivity. The ensemble model achieved strong performance metrics: binary accuracy (0.954), sensitivity (0.961), specificity (0.953), F1 score (0.836), and grade accuracy (0.932). Conclusions: This study demonstrates the feasibility of the use of LLMs for extraction and CTCAE toxicity grading in PCa patients treated with RT. The ensemble model achieved strong performance metrics. Further validation is needed for other cancer diagnosis and treatment modalities. Phase Model Binary Accuracy Precision Sensitivity Specificity F1 Score Grade Accuracy 1 Gemini 0.946 0.672 1.000 0.939 0.804 0.919 1 OpenAI 0.940 0.785 0.637 0.978 0.703 0.895 2 Gemini 0.956 0.735 1.000 0.950 0.848 0.927 2 OpenAI 0.954 0.917 0.679 0.991 0.780 0.903
TROPION-Urothelial03: A phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab
Galsky, Matthew D., Drakaki, Alexandra, Basu, Arnab, Bedke, Jens, Loriot, Yohann, Kikuchi, Eiji , Guo, Jun, Garmezy, Benjamin, Sridhar, Srikala S, Klauss, G., Lin, Daisy, Liu, Chelsea, Powles, Thomas, Galsky, Matthew D. , Drakaki, Alexandra , McGregor, Bradley A. , Bedke, Jens , Loriot, Yohann , Guo, Jun , Sridhar, Srikala S , Apolo, Andrea B , Powles, Thomas

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: No page available

10.1200/jco.2026.44.7_suppl.tps890 Get It

TPS890 Background: Although first-line (1L) EV + pembrolizumab has improved outcomes for patients with la/mUC, most experience disease progression, highlighting an unmet need for novel therapies. TROP2 is a glycoprotein highly expressed in several epithelial tumors, including UC. Dato-DXd is a TROP2-directed antibody–drug conjugate comprising an anti-TROP2 monoclonal antibody, a tetrapeptide-based cleavable linker, and a topoisomerase I inhibitor payload (DXd), designed to induce selective tumor-cell death and reduce systemic exposure to the payload. Dato-DXd has demonstrated durable efficacy and a manageable safety profile in patients with la/mUC both as monotherapy (TROPION-PanTumor01 [NCT03401385]) and in combination with immunotherapy (TROPION-PanTumor03 [NCT05489211]). We describe a phase 2/3 trial comparing the efficacy and safety of Dato-DXd + platinum CT (carboplatin or cisplatin) vs gemcitabine + platinum CT in participants with la/mUC with disease progression on or after EV + pembrolizumab. Methods: TROPION-Urothelial03 (NCT07129993) is a global, multicenter, randomized, open-label, phase 2/3 trial. In part A (phase 2), ~60 participants will be randomized 1:1 to receive Dato-DXd 4 or 6 mg/kg + platinum CT. In part B (phase 3), ~570 participants will be randomized 1:1 to receive Dato-DXd at the recommended phase 3 dose (determined using part A data) + platinum CT vs gemcitabine + platinum CT. Randomization in part A is stratified by assignment of platinum CT (carboplatin vs cisplatin), and in part B, by assignment of platinum CT, presence vs absence of liver metastasis at screening, and time to progression on 1L EV + pembrolizumab ( < 6 vs ≥6 months). Study treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, death, loss to follow-up, or other reasons per protocol. Radiographic tumor assessments occur every 6 weeks for 54 weeks, then every 12 weeks. The primary endpoint of part A is objective response rate (ORR) by investigator per Response Evaluation Criteria in Solid Tumours, version 1.1 (RECIST 1.1). The dual primary endpoints of part B are progression-free survival (PFS) by blinded independent central review (BICR) per RECIST 1.1 and overall survival (OS). Secondary endpoints include duration of response by investigator per RECIST 1.1 (part A), and PFS by investigator per RECIST 1.1 and ORR by BICR and investigator per RECIST 1.1 (part B). In part A, ORR will be summarized with 2-sided 95% exact confidence intervals using the Clopper–Pearson method by trial group. In part B, PFS and OS will be compared between trial groups using a log-rank test stratified by randomization stratification factors, with hazard ratios from the stratified Cox regression model. Clinical trial information: NCT07129993 .
Real-world early quality of life (QOL) changes on IO-based regimens in the prospective observational ODYSSEY metastatic renal cell carcinoma (mRCC) study.
Ged, Yasser , Maughan, Benjamin L., Bhavsar, Nrupen Anjan, Costello, Brian A. , Kilari, Deepak, Gupta, Sorab , Barbosa, Fernando Maciel, Monk, Paul, Vaishampayan, U., Jabusch, Sarah , Ward, Kimberly T., Wu, Yuan, Zhang, T., George, Daniel J., Vaishampayan, Ulka N. , Vaishampayan, Ulka , Harrison, Michael R. , Wulff, Elizabeth, Maughan, Benjamin L. , Bhavsar, Nrupen Anjan , Appleman, Leonard J. , Kilari, Deepak , Bratton, Melyssa R. , Monk, Paul , Rose, Tracy L. , Page, Courtney B , George, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 476-476

10.1200/jco.2026.44.7_suppl.476 Get It

476 Background: Lack of standardized reporting and collection of patient-reported outcomes (PROs) limits cross-trial comparisons of first-line IO-based regimens for mRCC. Prospectively collected real world data may fill this important knowledge gap. Pts with stable/improved QoL at 3 mo versus baseline have longer median OS than pts with worse/unobserved HRQoL versus baseline (Cella, 2024). Methods: ODYSSEY is a multi-site, prospective observational study of 468 US pts with mRCC. Pts must have mRCC (any histology), no prior systemic therapy (ST), and follow up at a PCORnet study site. Exclusion criteria include treatment for cancer except mRCC. Descriptive statistics are used to show PRO score changes from baseline. We evaluate longitudinal change from baseline in PRO scores using least squares mean (LSM). Minimally important differences (MID) are 3 points for FKSI-19 total score, 1 point for the FKSI-Disease Related Symptoms (DRS) subscale and 7 points for FACT-G. Higher score indicates better QOL. The primary objective is to determine patterns of change in QOL and symptom burden of pts with mRCC. Results: As of 10/1/25, 360 pts were managed with ST, including 266 pts on IO-based combinations: 35 cabozantinib + nivolumab (C+N), 49 lenvatinib + pembrolizumab (L+P), 40 axitinib + pembrolizumab (A+P), and 142 ipilimumab + nivolumab (I+N). Overall median follow-up is 12.1 mos (IQR 6, 24). Age, sex and race were similar across regimens. Prior nephrectomy (50%) was lower than in trials. C+N and L+P pts had less clear cell (56 and 65%) versus A+P and I+N pts (94 and 82%). A+P pts had more favorable IMDC risk (19%) and less poor risk (14%). Baseline QOL was variable across regimens, with L+P generally the lowest. Absolute changes in PROs from enrollment to mo 3 (early change) by regimen are shown in the Table. LSM change from baseline in FKSI-19 and FKSI-DRS favored IO-IO versus IO-TKI at 3 mos but not at 6 mos (not shown). Conclusions: While early change in PROs did not meet the MID threshold between the IO-TKI and I+N cohorts, different patterns of early change are apparent among specific IO-TKI regimens. IO-TKI regimens exhibited higher variation in early PRO change vs I+N. As the data matures, we will associate baseline PROs and early PRO changes with early death and other outcomes. Clinical trial information: NCT04919122 . 3 month change. Instrument C+N (N=35) L+P (N=49) A+P (N=40) All IO-TKI(N=124) I+N(N=142) FKSI-19, N (%) 26 (74) 33 (67) 33 (83) 92 (74) 104 (73) Mean (SD) -0.3 (11) 2.8 (13) -3.2 (12) -0.2 (12) 0.7 (10) Median (IQR) 1.4 (-7, 6) 5.0 (-7, 11) -1.0 (-14, 5) 1.4 (-10, 8) -0.3 (-5, 6) FKSI-DRS, N (%) 26 (74) 33 (67) 33 (83) 92 (74) 104 (73) Mean (SD) -0.8 (5) 1.5 (7) -1.8 (6) -0.3 (6) 0.8 (5) Median (IQR) -0.5 (-5, 3) 2.0 (-5, 5) -1.0 (-5, 3) 0.0 (-5, 4) 0.0 (-2, 4) FACT-G, N (%) 27 (77) 32 (65) 29 (73) 88 (71) 102 (72) Mean (SD) 2.1 (14) 5.2 (16) -3.5 (15) 1.4 (15) 0.3 (13) Median (IQR) 4.0 (-4, 10) 1.2 (-6, 13) -6.4 (-11, 4) 1.6 (-8, 10) 1.6 (-7, 8)
Total Thyroidectomy vs Lobectomy for Sporadic Medullary Thyroid Cancer
Lincango, Eddy, Vilatuna-Andrango, Luis, Arce-Camposano, Andrea, Mena-García, Cristina, Figueroa, Luis, Herold, Sarah, Zaldumbide, Matias, Pacheco, Fernanda Ventorim , Cayambe, Jennifer, Romero-Velez, Gustavo, Diaz, Jose Matias Zaldumbide , Lincango, Eddy P., Zaldumbide Diaz, Jose Matias , Lincango-Naranjo, Eddy , Andrango, Luis Vilatuna, Zaldumbide, Jose Matias, Pacheco, Fernanda, Quilligana, Jennifer Marisol Cayambe , Solís-Pazmiño, Paola , Westmoreland, Tamarah J. , Lew, John I. , Drake, Frederick Thurston , Romero-Vélez, Gustavo , Sosa, Julie Ann , Brito, Juan P.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | February 26, 2026 | Volume: 152 | Issue: 4 | Pages: 400

10.1001/jamaoto.2025.5599 | PMID 41746657 Get It

Importance Total thyroidectomy is the established surgical standard for hereditary and sporadic medullary thyroid cancer (sMTC). However, for unilateral sporadic tumors, its benefit over lobectomy remains uncertain. Objective To compare oncologic outcomes between total thyroidectomy and lobectomy in patients with sMTC. Data Sources and Study Selection MEDLINE, Embase, Scopus, and Cochrane Central Register of Controlled Trials were searched from inception to December 2025 to identify comparative studies on patients with sMTC who underwent total thyroidectomy or lobectomy. Data Extraction and Synthesis Reviewers working independently and in duplicate screened titles, abstracts, and full-text articles for eligibility using standardized instructions. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses ( PRISMA ) and Meta-Analysis of Observational Studies in Epidemiology ( MOOSE ) guidelines were used for reporting. Main Outcomes and Measures Primary outcomes were mortality, overall survival, structural recurrence, biochemical cure, and distant metastasis development. The secondary outcome was postoperative complications. Effect measures were calculated as odds ratios (ORs) or relative risks (RRs) with 95% CIs using a random-effects model. The risk of bias was assessed using the Newcastle-Ottawa Scale. Results Nine retrospective studies met inclusion criteria and comprised 1371 patients (295 of 397 patients [74.3%] with documented sex were female, and median age ranged from 45.0 to 58.2 years). A total of 531 patients (38.7%) underwent lobectomy and 840 (61.3%) underwent total thyroidectomy. Of 341 tumors, 280 (82.1%) lacked extrathyroidal extension, 284 of 401 tumors (70.8%) measured smaller than 2 cm (70.8%), and 197 of 343 tumors (57.4%) were node negative; central neck dissection was performed in 445 of 492 patients (90.4%). Multifocal disease was uncommon and reported in 30 of 330 patients (9.1%). Mortality did not differ at 5 years (RR, 0.30; 95% CI, 0.07-1.35) or beyond (RR, 1.00; 95% CI, 0.40-2.47). Overall survival at 5 years was similar (RR, 1.02; 95% CI, 0.94-1.11). Total thyroidectomy was not associated with lower structural recurrence rates at 5 years (OR, 0.45; 95% CI, 0.14-1.49), but it was associated beyond 5 years (OR, 7.26; 95% CI, 1.07-49.21). No differences were observed for biochemical cure at 5 years (OR, 0.86; 95% CI, 0.47-1.56) or beyond 5 years (OR, 0.87; 95% CI, 0.26-2.89). Distant metastasis development did not differ at 5 years (OR, 1.64; 95% CI, 0.09-31.52). Sensitivity analyses revealed no differences across any outcomes. Postoperative complications were more common in total thyroidectomy. Risk of bias was high in 4 studies, moderate in 4, and low in 1. Conclusions and Relevance Findings in this systematic review and meta-analysis, based on data from retrospective studies, suggest that thyroid lobectomy may be associated with oncologic outcomes comparable to total thyroidectomy in selected patients with sMTC.
Sarcomatoid urothelial carcinoma with constitutive PD-L1 overexpression
Gupta, Sounak, Kosari, Farhad , Thapa, Prabin , Murphy, Stephen J, Johnson, Sarah H. , Dashti, Nooshin K. , Tekin, Burak, Dasari, Surendra, Kipp, Benjamin R. , Sharma, Vidit, Shah, Paras H, Orme, Jacob J. , Frank, Igor, Karnes, R Jeffrey, Boorjian, Stephen A, Vasmatzis, George , Cheville, John C, Zarka, Jabra G, Orme, Jacob J , Murphy, Stephen J. , Greipp, Patricia T. , Tekin, Burak , Zarka, Jabra , Sharma, Vidit , Shah, Paras H., Frank, Igor, Karnes, R. Jeffrey, Boorjian, Stephen A. , Cheville, John C.

Mayo Clinic

Am J Clin Pathol | February 26, 2026 | Volume: 165 | Issue: 4 | Pages: No page available

10.1093/ajcp/aqag023 | PMID 41969028 Get It

Abstract Objectives Sarcomatoid urothelial carcinoma (sUC) is associated with poor clinical outcomes. Herein, we evaluated clinicopathologic features (including PD-L1 expression) for institutional cases. Methods Sixty-five patients with sUC treated by radical cystectomy were matched for age, sex, and pathologic stage to 190 patients with pure urothelial carcinoma (UC). Outcomes were evaluated using the Kaplan-Meier method. Immunohistochemistry (IHC) results for tumor-specific PD-L1 expression in sUC were quantified using H-scores (range, 0-300). Cases with constitutive PD-L1 expression (cPD-L1; H-score ≥240) were evaluated for amplification events using fluorescence in situ hybridization (n = 28), mate-pair sequencing (Mpseq; n = 6), RNA sequencing (n = 5), and targeted next-generation sequencing (n = 8). PD-L1 regulatory pathways were evaluated using gene set enrichment analysis in the Cancer Hallmark dataset. Results Most patients with sUC had advanced disease (≥pT2, 62/65, 95%), without significant differences in overall and cancer-specific survival, when matched to pure UC. Median PD-L1 H-scores using different clones were 100 (SP142), 120 (SP263), and 195 (22C3). cPD-L1 was seen in 43% (28/65) of cases of sUC that were enriched for TP53, TERT, and CDKN2A/B alterations. PD-L1 amplification was identified in 7 (of 28, 25%) of these cases. Bionformatics analysis consistently identified IL6-JAK-STAT3 and interferon α/γ signaling in sUC with cPD-L1 expression. Conclusions Our results suggest that cPD-L1 expression in most sUC occurs secondary to IL6-JAK-STAT3 and interferon α/γ signaling. This provides a biologic rationale for evaluating response to immunotherapy in this patient population.
Inflammation, Limbic White Matter Microstructure, and Clinical Symptoms in Retired American Football Players With Repetitive Head Impacts
Emanuel, Olivia M. , Miner, Annalise E., Lee, Shannon, Tanner, Jared J. , Holgerson, Allison A. , Tuz‐Zahra, Fatima , Tripodis, Yorghos, Adler, Charles H., Balcer, Laura J. , Bernick, Charles, Zetterberg, Henrik, Blennow, Kaj, Ashton, Nicholas J., Peskind, Elaine R. , Banks, Sarah J., Barr, W, Wethe, Jennifer V. , Cantu, Robert C., Coleman, Michael J., Dodick, David W., McClean, M M, Mez, Jesse, Palmisano, Joseph, Martin, Brett, Lin, Alexander P., Pasternak, Ofer , Cummings, Jeffrey L., Reiman, Eric M., Shenton, Martha E., Stern, Robert A., Bouix, Sylvain, Alosco, Michael L., Tripodis, Yorghos , Lee, Shannon Y. , Lee, Shannon Y , Matusz, Emily F , Tuz-Zahra, Fatima , Tripodis, Yorghos , Adler, C H , Balcer, Laura J , Bernick, Charles , Zetterberg, Henrik , Blennow, Kaj , Ashton, Nicholas J , Peskind, Elaine R , Banks, Sarah J , Barr, William B , Wethe, Jennifer V , Cantu, Robert C , Coleman, Michael J , Dodick, David W , McClean, Michael D , Mez, Jesse , Palmisano, Joseph , Martin, Brett , Lin, Alexander P , Pasternak, Ofer , Koerte, Inga K , Cummings, Jeffrey L , Reiman, Eric M , Shenton, Martha E , Stern, Robert A , Bouix, Sylvain , Alosco, Michael L , Asken, Breton M , Miner, Annalise E., Marsiske, Michael , Ly, Monica T. , Adler, Charles H. , Bernick, Charles , Blennow, Kaj , Ashton, Nicholas J. , Banks, Sarah J. , Barr, William , Cantu, Robert C. , Coleman, Michael J. , Dodick, David W. , Mez, Jesse , Palmisano, Joseph , Reiman, Eric M. , Shenton, Martha E. , Alosco, Michael L. , Asken, Breton M.

Mayo Clinic

Neurology | February 25, 2026 | Volume: 106 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000214646 | PMID 41740080 Get It